ASCO will grade drugs

The American Society of Clinical Oncology is taking notes. BioCentury reports that the professional society is grading cancer drugs based on benefit, toxicity and cost.

Chief Medical Officer Richard Schilsky told BioCentury that the scorecard is necessary because the price of a drug does not always reflect its impact.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.